THE IMPORTANCE OF SECONDARY PREVENTION IN SYSTEMIC SCLERODERMA
Keywords:
systemic scleroderma, secondary preventionAbstract
Systemic scleroderma is a multisystemic disease involving skin and internal organs (gastrointestinal tract, lungs, heart, kidneys, and peripheral nervous system). The pathogenesis of the disease includes dysfunction of the endothelium, epithelium, fibroblasts, as well as activation of the immune system and inflammatory mediators. In addition, the disease is characterized by impaired angiogenesis. Vasculopathy is the basis of pulmonary arterial hypertension, renal pathology, and digital ulcers. This article is devoted to a review of the diagnosis of systemic scleroderma, consideration of its secondary preventive criteria and approaches to treatment from the point of view of evidence-based medicine. This article provides an overview of the results of scientific research on the problem of systemic scleroderma over the past 10- 15 years.
References
Adigun R,Bhimji SS, Systemic Sclerosis (CREST syndrome), in StatPearls. 2017: Treasure Island (FL).
Agarwal SK,Reveille JD. The genetics of scleroderma (systemic sclerosis). Curr Opin Rheumatol 2010;22(2):133-8.
Akesson A, Hesselstrand R, et al. Longitudinal development of skin involvement and reliability of high frequency ultrasound in systemic sclerosis. Ann Rheum Dis 2004;63(7):791-6.
Al-Dhaher FF, Pope JE,Ouimet JM. Determinants of morbidity and mortality of systemic sclerosis in Canada. Semin Arthritis Rheum 2010;39(4):269-77.
Amanzi L, Braschi F, et al. Digital ulcers in scleroderma: staging, characteristics and sub-setting through observation of 1614 digital lesions. Rheumatology (Oxford) 2010;49(7):1374-82.
Aringer M, Muller-Ladner U, et al. [Common German language nomenclature for systemic sclerosis]. Z Rheumatol 2015;74(2):100-3.
Arnett FC, Cho M, Chatterjee S, Mayes MD. Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts. Arthritis and rheumatism. 2021 Jun:44(6)
Barnes J,Mayes MD. Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers. Curr Opin Rheumatol 2012;24(2):165-70.
Bellando-Randone S, Matucci-Cerinic M. From Raynaud's phenomenon to very early diagnosis of systemic sclerosis The VEDOSS approach. Curr Rheumatol Rev 2013;9(4):245-8.
Boin F,Rosen A, Autoimmunity in systemic sclerosis: current concepts. Current rheumatology reports. 2017 May
Burt R.K., Milanetti F. Hematopoietic stem cell transplantation for systemic sclerosis: history and current status. Curr. Opin. Rheumatol. 2019; 23(6): 519–29.
Burt R.K., Shah S.J., et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per months for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet. 2011; 378(9790): 498–506.
Bussone G, Mouthon L. Interstitial lung disease in systemic sclerosis. Autoimmun Rev 2011;10(5):248-55.
Cappelli L,Wigley FM. Management of Raynaud phenomenon and digital ulcers in scleroderma. Rheum Dis Clin North Am 2015;41(3):419-38.
Careta MF,Romiti R, Localized scleroderma: clinical spectrum and therapeutic update. Anais brasileiros de dermatologia. 2015 Jan-Feb
Cutolo M, Herrick AL, Distler O, et al. Nail fold videocapillaroscopic features and other clinical risk factors for digital ulcers in systemic sclerosis: A multicenter, prospective cohort study. Arthritis Rheumatol 2016;68(10):2527-39.
Cutolo M,Sulli A,Secchi ME,Paolino S,Pizzorni C, Nailfold capillaroscopy is useful for the diagnosis and follow-up of autoimmune rheumatic diseases. A future tool for the analysis of microvascular heart involvement? Rheumatology (Oxford, England). 2016 Oct
De Vries-Bouwstra J.k., Allanore Y., Matucci-Cerinic M. et al. Worldwide Expert Agreement on Updated Recommendations for the Treatment of Systemic Sclerosis. J. Rheumatol. 2020;.
Denton C.P., Khanna D. Systemic sclerosis. Lancet. 2017; 390(10103): 1685-99.
Denton C.P., Khanna D. Systemic sclerosis. Lancet. 2017; 390(10103): 1685–99.
Di Benedetto P., Ruscitti P., Cipriani P. et al. Haematopoietic stem cell transplantation in systemic sclerosis: Challenges and perspectives. Autoimmun. Rev. 2020; 19(11): 102662.
Fernandez-Codina A., Walker K.M., Pope J.E. et al. Treatment Algorithms for Systemic Sclerosis According to Experts. Arthritis Rheumatol. 2018; 70(11): 1820-28.
Pavlov-Dolijanovic S., Vujasinovic Stupar N., Zugic V. et al. Long-term effects of immunosuppressive therapy on lung function in scleroderma patients. Clin. Rheumatol. 2018; 37(11): 3043-50.
Sullivan K.M., Goldmuntz E.A., Keyes-Elstein L. et al. Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma. N. Engl. J. Med. 2018; 378(1): 35-47.
Volkmann E.R., Tashkin D.P., Sim M. et al. Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and II. J. Rheumatol. 2019; 46(10): 1316-25.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
